Agios Pharmaceuticals said it agreed with Celgene to end a three-year-old collaboration to develop and commercialize treatments containing its most advanced clinical cancer candidate AG-881 (vorasidenib), an oral inhibitor of both the isocitrate dehydrogenase-1 (IDH1) and IDH2 proteins. Agios stated in a regulatory filing that it will obtain sole global rights to AG-881. In return, Agios agreed to pay Celgene low-single-digit royalties on worldwide net sales of products containing AG-881—as well as split with Celgene worldwide development costs for AG-881 through December 31, 2018. According to the filing, Celgene and its affiliates are prohibited from developing, manufacturing, or commercializing any product that IDH1 at specified levels of binding for any indication—while Agios is barred from developing, manufacturing, or commercializing AG-881 in hematologic indications. The filing offered no reason for the termination. According to Agios’ Form 10-Q quarterly filing for the second quarter , Celgene may terminate ...
Original Article: Agios, Celgene End Collaboration to Develop Cancer Treatment AG-881